Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL6218477 | 0.99 | MEN1 (0.42) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| SCHEMBL6219114 | 0.91 | MEN1 (0.47) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| SCHEMBL6216542 | 0.91 | MEN1 (0.47) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| SCHEMBL6217147 | 0.89 | MEN1 (0.46) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| SCHEMBL6217205 | 0.89 | MEN1 (0.46) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| Maleic Acid SCHEMBL6583290 | 0.86 | HTR7 (0.43) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| Fumaric Acid SCHEMBL6581608 | 0.86 | HTR7 (0.43) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| Fumaric Acid SCHEMBL6580691 | 0.86 | HTR7 (0.43) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| SCHEMBL6581745 | 0.84 | SIGMAR1 (0.43) | MEN1KMT2AHTR1AADRA1AADRA1B | |
| SCHEMBL6216227 | 0.73 | CHRNA7 (0.51) | MEN1KMT2AHTR1ASIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307440-B1 | 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS | DOMPE SPA (IT) | 2005-03-09 | — | — | EP | claimed |
| US-20030176446-A1 | 2,2-disubstituted 1,3-dioxolanes as antitussive agents | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2003-09-18 | — | — | US | claimed |
| US-6916926-B2 | Process for the preparation of (±) 1-3-dioxolanes and the optical resolution thereof | DOMPE S.P.A. (IT) | 2005-07-12 | — | — | US | disclosed |
| EP-1307440-B1 | 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS | DOMPE SPA (IT) | 2005-03-09 | — | — | EP | disclosed |
| US-20030176446-A1 | 2,2-disubstituted 1,3-dioxolanes as antitussive agents | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2003-09-18 | — | — | US | disclosed |
| EP-1307440-A1 | 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS | Dompe' S.P.A. (IT) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010150-A1 | 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS | DOMPE' S.P.A. (IT) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176446-A1 | 2,2-disubstituted 1,3-dioxolanes as antitussive agents | ADRB2, QDPR, ADRB3 | ADRA1A 10/4885ADRA1B 17/4885ADRA2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.